Leukemia and Myeloproliferative Disorders
Show Only Open Trials
1.
Phase 1/2, Open-label, Dose-escalation, Multi-ctr Study to Assess Safety, Tolerability, PK, & PD of Oral NS-018 in Patients w/ Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
- Study Status: Open to Enrollment
- Sponsor: NS Pharma
- Disease Status and/or Stage: Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
2.
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
- Study Status: Open to Enrollment
- Sponsor: Agios Pharmaceuticals
- Disease Status and/or Stage: Advanced hematologic malignancies
3.
CALGB 100801: Phase II Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older patients With AML
- Study Status: Closed to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia and Myelodysplasia
- Protocol ID: CALGB 100801
4.
S1117: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplatic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
- Study Status: Closed to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Higher Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
- Protocol ID: S1117
5.
Phase III, Multicenter, Randomized, Trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus cytarabine and daunorubicin in patients 60-75 years of age with untreated high risk (secondary) AML (protocol CLTR0310-301)
- Study Status: Open to Enrollment
- Sponsor: Celator
- Disease Status and/or Stage: Newly Diagnosed High Risk AML, Age 60 to 75
6.
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Study Status: Closed to Enrollment
- Sponsor: Astellas Pharma
- Disease Status and/or Stage: Relapsed or Refractory Acute Myeloid Leukemia (AML); AC220; ASP2689; blood cancer treatment; Ellen Ritchie; Gail Roboz; Weill Cornell Leukemia: New York Presbyterian Hospital
7.
Phase II Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a diagnosis of Intermediate-2 or High-Risk PM, Post-PV Myelofibrosis, or Post-ET Myelofibrosis
- Study Status: Closed to Enrollment
- Sponsor: Sanofi Aventis
8.
Phase 3 randomized study to evaluate the substitution of Marqibo for standard vincristine sulfate injection in combination chemotherapy for subjects ≥ 60 yrs old w/ newly diagnosed ALL
- Study Status: Open to Enrollment
- Sponsor: Talon Therapeutics
- Disease Status and/or Stage: Newly Diagnosed ALL, Age 60 and Older
9.
10.
A Phase Ib Rising Multiple-Dose Clinical Study to Evaluate Safety, Tolerability, and Activity of Oral Monotherapy with KX2-391 in Elderly Subjects with Acute Myeloid Leukemia (AML) Who Are Refractory to or Have Declined Standard Induction Therapy
- Study Status: Closed to Enrollment
- Sponsor: Kinex
- Disease Status and/or Stage: Acute Myeloid Leukemia (AML) in Subjects Age 60 and Older
11.
A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms
- Study Status: Open to Enrollment
- Sponsor: Ely Lilly
- Disease Status and/or Stage: Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)
12.
Phase II randomized controlled trial of pegylated interferon alpha-2b in early primary myelofibrosis
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Low or Intermediate Stage Primary Myelofibrosis (PMF)
13.
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
- Study Status: Closed to Enrollment
- Sponsor: Memorial Sloan-Kettering Cancer Center
- Disease Status and/or Stage: Newly Diagnosed Acute Promyelocytic Leukemia
14.
An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Pfizer
- Disease Status and/or Stage: Relapsed/Refractory Acute Lymphoblastic Leukemia
15.
A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
- Study Status: Closed to Enrollment
- Sponsor: Ariad
- Disease Status and/or Stage: Newly Diagnosed Chronic Myeloid Leukemia
- Protocol ID: AP24534-12-301
16.
A Randomized study of Combined Haplo-identical Umbilical Cord Transplantation vs. Double Umbilical Cord Transplantation in Patients with Hematologic Malignancies
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
17.
A Prospective Study of Optimally Matched-IPA Targeted Haplo-cord Transplantation
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematologic Malignancies in Need of Donor Stem Cell Transplant
18.
BMT CTN 0903 - Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals
- Study Status: Open to Enrollment
- Sponsor: BMT-CTN
- Disease Status and/or Stage: Hematologic Cancers and Myelosysplastic Syndromes in HIV-Positive People
- Protocol ID: BMT CTN 0903
19.
CALGB 10701: A Phase II Study of Dasatinib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy followed by Transplantation for Adults ≥ 50 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Protocol ID: CALGB 10701
20.
CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning (RIC) Stem Cell Transplantation Utilizing Double Umbilical Cord Blood (dUCB) Grafts for Patients with Relapsed or Refractory Leukemia
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed/Refractory Leukemia
21.
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
- Study Status: Open to Enrollment
- Sponsor: Myeloproliferative Disorders-Research Consortium
- Disease Status and/or Stage: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
- Protocol ID: MPD-RC 111
22.
Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)
- Study Status: Closed to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Polycythemia Vera (PV)
23.
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
- Study Status: Closed to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
24.
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia
- Study Status: Open to Enrollment
- Sponsor: Plexxikon
25.
CALGB 11002 - A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients ≥ 60 Years Old With Acute Myeloid Leukemia (AML)
- Study Status: Closed to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Acute Myeloid Leukemia
26.
Treatment Decision Making in Elderly Patients with Hematological Malignancies: New Approaches to an Old Problem
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Hematological Malignancies
27.
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
- Study Status: Closed to Enrollment
- Sponsor: Sunesis Pharmaceuticals
- Disease Status and/or Stage: Acute Myeloid Leukemia or Acute Nonlymphocytic Leukemia
28.
Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine
- Study Status: Closed to Enrollment
- Sponsor: Onconova Therapeutics, Inc
- Disease Status and/or Stage: Myelodysplastic Syndromes (MDS) Including RAEB and Chronic Myelomonocytic Leukemia (CMML)
29.
CALGB 10403: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
- Study Status: Closed to Enrollment
- Sponsor: CALGB; NCI; Eastern Cooperative Oncology Group; Southwest Oncology Group
- Disease Status and/or Stage: Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
- Protocol ID: CALGB 10403
30.
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
- Study Status: Closed to Enrollment
- Sponsor: Myeloproliferative Disorders-Research Consortium
- Disease Status and/or Stage: Polycythemia Vera (PV)
31.
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Imtermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Study Status: Closed to Enrollment
- Disease Status and/or Stage: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
